Dr. Neeraj Agarwal

Dr. Neeraj Agarwal is a Professor of Medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), University of Utah. He also directs the Genitourinary Oncology (GU) Program and the Center of Investigational Therapeutics (CIT) at the HCI. Dr. Agarwal is a medical oncologist and an internationally recognized physician-scientist in the field of genitourinary cancers, particularly prostate cancer. He has received the SWOG Young Investigator Award, the William D. Odell Young Investigator Award, and a National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award, and recognition as a Fellow of the American Society of Clinical Oncology (FASCO). Dr. Agarwal also serves as the Senior Director (aka Associate Director) of clinical research, overseeing the clinical and late translation research at the HCI, an NCI-designated comprehensive cancer center.

He has been the study chair or steering committee member of trials leading to FDA and EMA approval of apalutamide, olaparib, and talazoparib for patients with metastatic prostate cancer. Agarwal has developed a number of experimental agents in the prostate, renal cell, and bladder cancer, including completed or ongoing trials of AR inhibitors, radiopharmaceuticals such as radium, lutetium-177, Actinium-225, AR degraders, PARP inhibitors such as talazoparib, olaparib, niraparib, and saruparib, a tyrosine kinase inhibitor, cabozantinib, and EZH2 inhibitor, mevrometostat. He has published in developing biomarkers associated with response to therapy in advanced prostate cancer (HSD3B1, SPOP, TSG loss). Furthermore, Dr. Agarwal currently serves as the principal investigator (mPI) of an NCI-funded R01 grant. He has received multiple awards for mentoring, including the Guy A. Zimmerman, MD, Faculty Mentoring Award, Outstanding Faculty Mentorship Award at the University of Utah, and the American Society of Clinical Oncology (ASCO) Mentor Award (for students from underrepresented populations).

After receiving his medical training at the All-India Institute of Medical Sciences in New Delhi, he completed an internal medicine residency and a geriatric medicine fellowship at the University of Iowa, followed by a hematology-oncology fellowship at HCI. He has authored or co-authored over 550 scientific publications and numerous book chapters and abstracts. He serves or served as a panel member for the NCCN, ESMO, and ASCO guidelines committees for genitourinary cancers and the leader of early therapeutics for the SWOG GU cancers committee for more than a decade. He has served as the editorial board member of several journals, including the Journal of Clinical Oncology and European Urology, and currently serves as an ASCO Genitourinary Cancers Advisory Panel member, as well as the chief editor of the ASCO Daily News.